127017-78-1

Basic information

• Product Name: 3R,4S-4-(4-methoxyphenyl)-1-methylpiperi dinyl] methanol
• Synonyms: 3R,4S-4-(4-methoxyphenyl)-1-methylpiperi dinyl] methanol;[(3R,4S)-4-(4-Methoxyphenyl)-1- methylpiperidinyl]methanol,98%e.e.
• CAS NO: 127017-78-1
• Molecular Formula: C14H21NO2
• Molecular Weight: 235.32
• Mol File: 127017-78-1.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3R,4S-4-(4-methoxyphenyl)-1-methylpiperi dinyl] methanol(CAS DataBase Reference)
• NIST Chemistry Reference: 3R,4S-4-(4-methoxyphenyl)-1-methylpiperi dinyl] methanol(127017-78-1)
• EPA Substance Registry System: 3R,4S-4-(4-methoxyphenyl)-1-methylpiperi dinyl] methanol(127017-78-1)

Safety Data

• Hazardous Substances Data: 127017-78-1(Hazardous Substances Data)

Usage

General Description

The chemical "3R,4S-4-(4-methoxyphenyl)-1-methylpiperidinyl] methanol" is a specific stereoisomer of a compound that contains a piperidine ring and a methanol group. It has a methyl group attached to the piperidine ring, as well as a 4-methoxyphenyl group. This chemical is commonly used in pharmaceutical research and development due to its potential biological activity and therapeutic properties. It may have applications in the treatment of various medical conditions, although further research is necessary to fully understand its potential uses and effects.

Upstream product

• 63-75-2 arecoline 
• 104-92-7 1-bromo-4-methoxy-benzene 

Relevant articles and documents

NOVEL PROCESS FOR THE PREPARATION OF 4-ARYL-3-HYDROXYMETHYL-1-METHYLPIPERIDINES.

A novel, improved, and general process for the preparation of 4-aryl-3-hydroxymethyl-1-methylpiperidines is disclosed in the present invention. 4-(4-Fluorophenyl)-3-hydroxymethyl-1-methylpiperidine is a well-known intermediate in making the anti-depressan

Method of treating calcium overload

Novel piperidine compounds having the formula STR1 wherein R3 is 3,4-methylenedioxyphenyl, aryl or heteroaryl which are optionally substituted with one or more halogen, C1-6 -alkoxy, optionally substituted aryloxy or aryl-C1-6 -alkoxy, cyano, mono or poly halogenated C1-6 -alkyl, C1-6 -alkenyl, C1-6 -alkyl, C3-5 -alkylene or trifluoromethyl groups, R1 is straight or branched C1-8 -alkyl unsubstituted or substituted with one or more cyano, ester, dialkylamino, hydroxy, amido, halogeno, substituted or unsubstituted piperidino, morpholino, thiomorpholino, dioxolanyl, tetrahydrofuranyl, C1-8 -alkoxy or C3-8 cycloalkyl groups, X is hydrogen, halogen, trifluoromethyl, hydroxy cyano or C1-8 -alkoxy, Y is O or S; provided that R1 is not unsubstituted C1-8 -alkyl, when R3 is 3,4-methylenedioxyphenyl, aryl or heteroaryl optionally subsituted with one or more C1-6 -alkyl, C1-6 -alkoxy, C3-5 -alkylene, C3-8 -cycloalkyl or aralkoxy, and at the same time X is hydrogen or halogen and a salt thereof with a pharmaceutically acceptible acid. The novel compounds are useful in the treatment of anoxia, migraine, ischemia and epilepsy.